IGF-1 LR3

IGF-1 LR3 is a structurally modified form of insulin-like growth factor I developed to alter its interactions with binding proteins and its biological availability. It has been investigated in growth-related research, but the supplied material does not establish therapeutic benefits or safety in humans.

IGF-I participates in cellular growth and metabolic signaling within the broader growth hormone–IGF system. IGF-binding proteins influence its availability to tissues and receptors. The supplied guide attributes altered biological persistence to structural changes in IGF-1 LR3, although it provides no supporting pharmacokinetic evidence.

The guide describes weaker interactions with IGF-binding proteins as a mechanism that could increase the fraction available for receptor signaling. IGF-I receptor activity is relevant to the proposed effects on protein production and cellular growth. These mechanisms should not be equated with prolonging the activity of growth hormone itself.

1. 01

   Molecular target

2. 02

   Cellular signal

3. 03

   Biological process

LEVEL 02 · Preclinical research

Laboratory or animal research exists. Findings do not transfer reliably to people.

Evidence levels reflect the state of documented research only. They are not rankings of popularity, quality or suitability, and a higher level never implies that a compound is an approved medicine.

The source guide presents IGF-1 LR3 as an engineered IGF-I analogue with reduced binding-protein affinity and longer biological persistence. It associates the compound with muscle development, recovery, changes in fat metabolism, and tissue repair, without supplying evidence sufficient to verify those outcomes. It also raises concerns about glucose lowering, abnormal organ enlargement, joint discomfort, and fluid accumulation.

Source: The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Summarised in our own wording from the cited reference. The reference is a popular guide, not peer-reviewed literature; its statements are reported here as source claims rather than established facts.

Dosage, reconstitution and administration guidance is deliberately excluded from this platform.

The supplied notes do not establish the magnitude, duration, or clinical relevance of the proposed effects. Human outcomes, long-term risks, and the guide's assertion about receptor desensitization remain insufficiently supported.

Safety data are limited, particularly for human exposure and long-term outcomes. Potential concerns described in the guide include hypoglycemia, unwanted tissue or organ growth, joint symptoms, and fluid retention, but their frequency and severity are not established by the supplied material. This information is not medical advice.

Research-stage compound unless otherwise established by a competent authority. Regulatory classification differs between jurisdictions and can change over time; nothing here indicates marketing authorisation.

Primary reference for this entry:

The Complete Guide to Peptides: Unlocking the Secrets to Health, Healing and Longevity — Hack Smith, Chapter 6, Introduction to Peptides (page references not verified)

Suggested literature search terms taken from the source. They are search starting points, not citations to specific studies.

• “IGF-1 LR3 anabolic muscle growth effects”
• “IGF-1 LR3 peptide for recovery and regeneration”
• “IGF-1 LR3 fat metabolism and performance enhancement”

Editorial status

source reviewed

Last updated

2026-09-14

Last reviewed

2026-09-13

Language

EN